Page 2 - Pharma

Punjab bans Coldrif, even as PIL in SC seeks probe on cough syrup deaths

With this, the state joins Maharashtra, Kerala and Tamil Nadu, who have already announced bans on the cough syrup

Eli Lilly's Mounjaro logs ₹80 crore in September, India's No. 2 drug

Eli Lilly's weight-loss injection Mounjaro saw a 42% jump in September sales, touching Rs 80 crore as more patients shift to higher doses amid rising demand

Rubicon Research sets IPO price band at ₹461-475; check key dates, lot size

Rubicon Research IPO will open for subscription on Thursday, October 9, 2025, and close on Monday, October 13, 2025

Govt invites proposals under PRIP scheme for pharma, medtech projects

DoP recently notified revised guidelines to make scheme better suited for stakeholders

Trump’s 100% tariff shock on pharma: What it means for India, pharma stocks?

US President Donald Trump has once again rattled markets with his tariff announcement, this time targeting the pharmaceutical sector.

7 out of 10 digital projects in India's pharma sector fail: Vector study

Vector Consulting Group study finds pharma firms spend up to ₹75 cr annually on IT systems, but 70% of digital projects fail due to adoption gaps and poor execution

Novartis signs $5.7 bn licensing deal with Monte Rosa Therapeutics

Under the agreement, Monte Rosa will receive an upfront payment of $120 million and could earn milestone payments and royalties that lift the total value to as much as $5.7 billion

NPPA asks pharma firms to pass on GST rate cut benefits from Sept 22

The National Pharmaceutical Pricing Authority has asked pharmaceutical companies and medical device makers to pass on the benefit of reduced GST rates to consumers with effect from September 22. "The benefit of reduction in GST rates shall be passed on to consumers/patients effective from September 22, 2025. All the manufacturers /marketing companies selling drugs/formulations shall revise theP of drugs/formulations (including medical devices) accordingly, with effect from September 22," the authority said in an order. The manufacturer and marketing companies shall issue a revised price list or supplementary price list to the dealers, retailers, state drug controllers and the government, reflecting the revised GST rates and revisedP, the National Pharmaceutical Pricing Authority (NPPA) stated. Manufacturer and marketing companies shall take immediate measures to sensitise dealers, retailers, and consumers about the reduction in GST rates through all possible channels of communicatio

Are ethical pharma practice norms 'actually' implemented, asks SC

The Supreme Court on Thursday said the actual "difficulty" was in the implementation of the existing norms while hearing a plea seeking an uniform code for marketing practices of pharmaceutical firms to curb any unethical ways to promote drugs. Justices Vikram Nath and Sandeep Mehta made the observation after Solicitor General Tushar Mehta, appearing for the Centre, said the prayer made in the plea had become infructuous as a statutory regime was already in place. "The difficulty is, regime is there in place, but whether that is actually implemented or not," Justice Nath said. Senior advocate Kapil Sibal, who also appeared in the matter, said a new regime was brought in last year. "That is what the concern of mylords is, that if it is a toothless tiger... what is the purpose," Justice Mehta said. The law officer, however, responded, "It is a tiger with all power at its command". The Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024 came in force last year. Mehta .

No additional tariffs by US on Indian pharma, electronics so far: Govt

The government on Tuesday said no additional tariffs have been imposed on Indian exports to the US in sectors like pharmaceuticals, and electronics so far. In a written reply to the Lok Sabha, Minister of State for Commerce and Industry Jitin Prasada said reciprocal tariff at the rate of 25 per cent has been imposed on certain goods exported from India to the US, effective August 7. It is estimated that around 55 per cent of the total value of India's merchandise exports to the US is subjected to this reciprocal tariff, he said, adding that additional ad valorem rate of duty of 25 per cent with effect from August 27 has been imposed on certain goods exported from India. "No additional tariffs have been imposed on Indian exports to the US in sectors like pharmaceuticals, and electronics as yet," Prasada said. He also said the government is engaged with all stakeholders, including exporters and industry, for taking feedback of their assessment of the impact from the reciprocal tariff

Confident about Biocon's response to US tariffs: Kiran Mazumdar-Shaw

We remain confident in our global footprint and are well positioned to respond once more details are available. , said Biocon Chairperson

Pharma firms get one-month extension to submit declarations under UCPMP

The Department of Pharmaceuticals extends the deadline for pharma companies to file self-declarations, ensuring compliance with the Uniform Code for Pharmaceutical Marketing Practices (UCPMP)

Cipla Q1 preview: Net profit may jump up to 4%, revenue by 8% YoY

Cipla is scheduled to announce its April-June quarter earnings for the financial year 2025-26 (Q1FY26) on Friday, July 25, 2025

806 applications approved so far under PLI schemes across 14 sectors

The government on Tuesday said as many as 806 applications have been approved under the Production Linked Incentive (PLI) schemes across 14 sectors as on date. The schemes for 14 key sectors including telecom, electronics, pharma, textiles and auto were announced with an outlay of Rs 1.97 lakh crore to enhance India's manufacturing capabilities and exports. It was announced in 2021. "As on date, 806 applications have been approved under PLI schemes across 14 sectors," Minister of State for Commerce and Industry Jitin Prasada said in a written reply to the Lok Sabha. He said that actual investment of Rs 1.76 lakh crore has been realised till March 2025 across 14 sectors, which has resulted in incremental production/sales of over Rs 16.5 lakh crore and employment generation of over 12 lakh (direct and indirect jobs). The pharmaceuticals sector has witnessed cumulative sales of Rs 2.66 lakh crore, which includes exports of Rs 1.70 lakh crore achieved in the first three years of the ..

Researchers map hair growth pathways for non-surgical hair restoration

The Esthetic Clinics and QR678 Research collaborate on groundbreaking research mapping hair growth pathways, potentially offering a non-surgical solution to hair restoration.

Wockhardt exits US generics biz, to focus on innovative portfolio

Wockhardt exits the US generics market after years of losses, shifting focus to new antibiotic drug discovery and biologicals, including insulin, to create long-term value.

HC grants relief to Galderma against infringers using 'CETAPHIL' trademark

Bombay HC issues John Doe injunction allowing Galderma to take immediate action against counterfeit CETAPHIL products; seizures made in New Delhi and Mumbai

Lupin launches nasal spray in US, part of 200-drug pipeline by FY30

The product, launched in the US market, is a generic version of Atrovent and part of Lupin's plan to scale complex generics revenue share to 62 per cent by FY30

Emcure Pharma shares dip after 2.4% stake change hands in block trades

Emcure Pharma shares fell after about 4.53 million shares, or a 2.4 per cent stake, changed hands via block trades on the NSE

Biocon Biologics gets EU nod for two drugs to treat bone diseases

Biocon Biologics receives marketing authorisation from the European Commission for two Denosumab biosimilars, Vevzuo and Evfraxy, expanding its portfolio in bone disease treatment